<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01712412</url>
  </required_header>
  <id_info>
    <org_study_id>ICP-112-201</org_study_id>
    <nct_id>NCT01712412</nct_id>
  </id_info>
  <brief_title>Phase 2a Study of IW-9179 to Treat Functional Dyspepsia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ironwood Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ironwood Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to determine the safety and efficacy of IW-9179 administered
      to patients with functional dyspepsia (FD).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow enrollment
  </why_stopped>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of treatment-emergent adverse events</measure>
    <time_frame>Reported at any time after the first dose, including the 14 days of treatment and 7 days of follow up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline 12-lead electrocardiogram (ECG) at day 14 of treatment</measure>
    <time_frame>Baseline values taken just prior to first dose (day 1) compared with values taken on the last day of treatment (day 14)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline clinical laboratory evaluations at the last day of treatment (day 14)</measure>
    <time_frame>Baseline values taken just prior to first dose (day 1) compared with values taken on the last day of treatment (day 14)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline vital signs at the day 14 visit and at the end of the study (7 days after the last dose)</measure>
    <time_frame>Baseline values taken prior to first dose (day 1) compared with values taken at the day 14 visit (14 days after first dose) and at the end of the study (21 days after the first dose)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-meal Symptom Severity (PMSS) Assessment</measure>
    <time_frame>Completed at day 1 and day 14 of the Treatment Period</time_frame>
    <description>Assessments completed at 15 min prior to dose, just prior to dose, and every 15 minutes after the first dose through 240 minutes (4 hours after first dose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Patient Symptom Severity (PSS) Assessment</measure>
    <time_frame>Average of daily assessments for the 2 weeks just prior to the first dose compared to: 1) the average of the 2 week treatment period, 2) the average of the first week of treatment and 3) the average of the second week of treatment</time_frame>
    <description>Assessments recorded on a daily basis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Symptom Relief (SR) Assessments</measure>
    <time_frame>Average of week 1 and week 2 prior to treatment compared with the week 1 and week 2 during treatment</time_frame>
    <description>Assessments recorded on a weekly basis weekly</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nepean Dyspepsia Index</measure>
    <time_frame>Baseline NDI score (collected just prior to first dose) compared with End of Treatment NDI (collected just prior to last dose)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Dyspepsia</condition>
  <condition>Functional Gastrointestinal Disorders</condition>
  <arm_group>
    <arm_group_label>IW-9179</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral IW-9179 taken daily for two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo taken daily for two weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IW-9179</intervention_name>
    <arm_group_label>IW-9179</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient meets ROME III criteria for functional dyspepsia (FD)

          -  Patient has a normal esophagogastroduodenoscopy (EGD) either during the Screening
             Period or within 2 years of the Screening Visit

          -  Patients who EITHER:

               1. Have not used a proton pump inhibitor (PPI) within 4 weeks of the Screening
                  Visit, OR

               2. Have used a PPI at a stable dose for at least 4 weeks prior to the Screening
                  Visit;

          -  Patient meets symptom severity criteria in the Pretreatment Period

          -  Patient is fluent and literate in Dutch, French, or English

        Exclusion Criteria:

          -  Patient meets criteria for gastroesophageal reflux disease (GERD, stable regimen of
             PPIs acceptable), constipation, diarrhea, lower abdominal pain, or gastroparesis

          -  Patient has a history of inflammatory bowel disease, chronic pancreatitis, small
             intestinal bacterial overgrowth, celiac disease, lactose intolerance, polycystic
             kidney disease, interstitial cystitis, or scleroderma

          -  Any significant neurological disease or a history of cancer (resected basal cell or
             squamous cell carcinoma of the skin is acceptable; complete remission of other cancers
             for 5 years or longer is also acceptable)

          -  History of active alcoholism or drug addiction within 12 months prior to the Screening
             Visit

          -  Hospitalized for a psychiatric condition or has made a suicide attempt during the two
             years before the Screening Visit

          -  Any organic or structural disease that can cause abdominal pain or discomfort
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AZ Sint-Lucas Brugge</name>
      <address>
        <city>Brugge</city>
        <zip>8310</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Z.O.L. - Campus St. Jan</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Ambroise Pare</name>
      <address>
        <city>Mons</city>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Hartziekenhuis Roselare-Menen vzw</name>
      <address>
        <city>Roselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FlevoResearch</name>
      <address>
        <city>Almere</city>
        <zip>1311 RL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PreCare Trial and Recruitment</name>
      <address>
        <city>Beek</city>
        <zip>6191 JW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Breda</name>
      <address>
        <city>Breda</city>
        <zip>4811 SW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Eindhoven</name>
      <address>
        <city>Eindhoven</city>
        <zip>5616GB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Noord</name>
      <address>
        <city>Groningen</city>
        <zip>9711 SG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Leiden</name>
      <address>
        <city>Leiden</city>
        <zip>2352 RA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht University Med Ctr</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <zip>3021 HC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2012</study_first_submitted>
  <study_first_submitted_qc>October 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2012</study_first_posted>
  <last_update_submitted>March 18, 2014</last_update_submitted>
  <last_update_submitted_qc>March 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

